The preoperative neutrophil‐to‐lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy-Reference-Cited by-同舟云学术

The preoperative neutrophil‐to‐lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy

Published:2019-01-28 Issue:3 Volume:8 Page:1004-1012
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Cao Zhi¹^ORCID,Ji Jin¹,Zhang Chao¹,Wang Fubo¹,Xu Huan¹,Yu Yongwei²,Sun Yinghao¹

Affiliation:

1. Department of Urology Changhai Hospital Navy Medical University Shanghai P. R. China

2. Department of Pathology Changhai Hospital Navy Medical University Shanghai P. R. China

Funder

National Natural Science Foundation of China

Foundation of Shanghai Municipal Commission of Health and Family Planning

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1984

Reference24 articles.

1. Cancer statistics, 2014

2. Prostate cancer in East Asia: evolving trend over the last decade

3. Pretreatment Neutrophil-to-Lymphocyte Ratio

4. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis

5. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Negative Impact of Inflammation-Related Parameters in Prostate Cancer after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (the MSUG94 Group);Journal of Clinical Medicine;2023-12-17

2. Pretreatment Pan-Immune-Inflammation Value (PIV) in Predicting Therapeutic Response and Clinical Outcomes of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma;Annals of Surgical Oncology;2023-10-14

3. The neutrophil-to-lymphocyte ratio as a new prognostic factor in cancers: a narrative review;Frontiers in Oncology;2023-10-04

4. Clinical utility of preoperative pan-immune-inflammation value (PIV) for prognostication in patients with esophageal squamous cell carcinoma;International Immunopharmacology;2023-10

5. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review;Asian Journal of Urology;2023-02